Salient Private Client’s Pfizer PFE Stock Holding History

Salient Private Client’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$1.49M	Sell	35,563 -453	-1%	-$17.4K	0.29%	64
2018 Q2	$1.24M	Sell	36,016 -10,106	-22%	-$345K	0.21%	85
2018 Q1	$1.55M	Sell	46,122 -11,678	-20%	-$401K	0.27%	77
2017 Q4	$1.99M	Buy	+57,800	New	+$1.97M	0.41%	59

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Salient Private Client's PFE Position: Q3 2018 in Review

Salient Private Client reduced its Pfizer (PFE) stake by 1.3% in Q3 2018, selling an estimated $17.4K and leaving 35,563 shares worth $1.49M. The position accounts for 0.29% of the portfolio, ranked #64.

Salient Private Client first reported a position in PFE in Q4 2017 and has held it in 4 quarters since. The position peaked at $1.99M in Q4 2017. 2,256 funds tracked by Wall St. Rank hold PFE as of Q3 2018.

Salient Private Client held 35,563 shares of Pfizer worth $1.49M as of Q3 2018.
Salient Private Client sold 453 Pfizer shares in Q3 2018, an estimated $17.4K.
Pfizer made up 0.29% of Salient Private Client's portfolio in Q3 2018, its #64 holding.
Salient Private Client first reported a position in Pfizer in Q4 2017 and has held it in 4 quarters since.
Salient Private Client's Pfizer position peaked at $1.99M in Q4 2017.
2,256 funds tracked by Wall St. Rank held Pfizer as of Q3 2018.

Based on Salient Private Client's 13F filing for Q3 2018, filed 14 Nov 2018.